BioPharmX Corporation released phase 2b clinical data

Written by   BioPharmX

BioPharmX Corporation, a Silicon Valley pharmaceutical company, released phase 2b clinical data showing its investigational drug BPX-01 2% reduces acne lesions by 59 percent with no drug-related adverse events – and suggesting it may also lessen lesions’ severity. BPX-01 2% topical minocycline gel was superior in reducing the number of lesions in patients with moderate-to-severe acne, compared to vehicle (59 versus 44 percent). Evaluations using a five-point investigator’s global assessment scale also showed more two-grade improvements, compared to vehicle (29.2 versus 17.6 percent). Researchers detected no minocycline in patients’ bloodstreams, except for a single outlier whose level was one tenth that of oral minocycline.

Want to read more?

Log in or subscribe to continue reading this article.

Login to post comments

The Best in the Biz

Stephanie Andresen-Stevens

Anna Babinksa

Emily Davis

Elina Fedotova